{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:35:29Z","timestamp":1792197329828,"version":"4.4.0"},"reference-count":181,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":645,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000092","name":"U.S. National Library of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1038\/mto.2015.17","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T10:55:38Z","timestamp":1444820138000},"page":"15017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Oncolysis by paramyxoviruses: preclinical and clinical studies"],"prefix":"10.1016","volume":"2","author":[{"given":"Olga V","family":"Matveeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong S","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav M","family":"Senin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V","family":"Senina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana A","family":"Shabalina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M","family":"Chumakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mto.2015.17_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00000441-190412740-00001","article-title":"The influence of complicating diseases upon leukemia","volume":"127","author":"Dock","year":"1904","journal-title":"Am J Med Sci"},{"key":"10.1038\/mto.2015.17_bib2","first-page":"82","article-title":"Sulla scomparsa di un enorme cancro vegetante del collo dell'utero senza cura chirurgica","volume":"9","author":"De Pace","year":"1912","journal-title":"Ginecologia"},{"key":"10.1038\/mto.2015.17_bib3","first-page":"443","article-title":"Vaccine et neoplasmes","volume":"37","author":"Levaditi","year":"1923","journal-title":"Ann Inst Pasteur"},{"key":"10.1038\/mto.2015.17_bib4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"N Engl J Med"},{"key":"10.1038\/mto.2015.17_bib5","first-page":"688","article-title":"[Viruses and tumors]","volume":"5","author":"Svejda","year":"1950","journal-title":"Lek List"},{"key":"10.1038\/mto.2015.17_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev.mi.08.100154.002141","article-title":"Effects of viruses on tumors","volume":"8","author":"Moore","year":"1954","journal-title":"Annu Rev Microbiol"},{"key":"10.1038\/mto.2015.17_bib7","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.17_bib8","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1158\/1078-0432.CCR-11-2181","article-title":"Phase I\/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies","volume":"18","author":"Karapanagiotou","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.17_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"key":"10.1038\/mto.2015.17_bib10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrd4643","article-title":"Oncolytic viruses get a boost with first FDA-approval recommendation","volume":"14","author":"Dolgin","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1038\/mto.2015.17_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.gde.2010.10.008","article-title":"Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications","volume":"21","author":"De Bock","year":"2011","journal-title":"Curr Opin Genet Dev"},{"key":"10.1038\/mto.2015.17_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4155\/tde.10.9","article-title":"Nucleic acid therapeutics: concepts for targeted delivery to solid tumors","volume":"1","author":"Ogris","year":"2010","journal-title":"Ther Deliv"},{"key":"10.1038\/mto.2015.17_bib13","first-page":"238","article-title":"Sweet escape: sialic acids in tumor immune evasion","volume":"1846","author":"B\u00fcll","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"6C","key":"10.1038\/mto.2015.17_bib14","first-page":"4943","article-title":"CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients","volume":"26","author":"Surowiak","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1038\/mto.2015.17_bib15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/PAI.0b013e31821a0be9","article-title":"CD46 Expression is an unfavorable prognostic factor in breast cancer cases","volume":"19","author":"Maciejczyk","year":"2011","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/mto.2015.17_bib16","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/0008-5472.CAN-09-0016","article-title":"Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer","volume":"69","author":"Takano","year":"2009","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1309\/AJCPGXK0FR4MHIHB","article-title":"Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker","volume":"134","author":"Derycke","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/mto.2015.17_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10719-006-5433-0","article-title":"Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview","volume":"23","author":"Villar","year":"2006","journal-title":"Glycoconj J"},{"key":"10.1038\/mto.2015.17_bib19","doi-asserted-by":"crossref","first-page":"e1002240","DOI":"10.1371\/journal.ppat.1002240","article-title":"Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus","volume":"7","author":"Noyce","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1038\/mto.2015.17_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tim.2012.05.006","article-title":"Nectin 4 is the epithelial cell receptor for measles virus","volume":"20","author":"Noyce","year":"2012","journal-title":"Trends Microbiol"},{"key":"10.1038\/mto.2015.17_bib21","first-page":"95","article-title":"The genes of interferons and interferon-related factors: localization and relationships with chromosome aberrations in cancer","volume":"48","author":"Haus","year":"2000","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1038\/mto.2015.17_bib22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrmicro1927","article-title":"Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded","volume":"6","author":"Cattaneo","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"10.1038\/mto.2015.17_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","article-title":"New functions for the matrix metalloproteinases in cancer progression","volume":"2","author":"Egeblad","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mto.2015.17_bib24","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s13277-013-0842-8","article-title":"Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets","volume":"34","author":"Hadler-Olsen","year":"2013","journal-title":"Tumour Biol"},{"key":"10.1038\/mto.2015.17_bib25","doi-asserted-by":"crossref","first-page":"e1000973","DOI":"10.1371\/journal.ppat.1000973","article-title":"Paramyxovirus entry and targeted vectors for cancer therapy","volume":"6","author":"Cattaneo","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1038\/mto.2015.17_bib26","doi-asserted-by":"crossref","first-page":"e38052","DOI":"10.1371\/journal.pone.0038052","article-title":"Respiratory syncytial virus matrix protein induces lung epithelial cell cycle arrest through a p53 dependent pathway","volume":"7","author":"Bian","year":"2012","journal-title":"PLoS One"},{"key":"10.1038\/mto.2015.17_bib27","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1084\/jem.20080383","article-title":"Transcriptional role of p53 in interferon-mediated antiviral immunity","volume":"205","author":"Mu\u00f1oz-Fontela","year":"2008","journal-title":"J Exp Med"},{"key":"10.1038\/mto.2015.17_bib28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/v2010298","article-title":"Dual Role of p53 in Innate Antiviral Immunity","volume":"2","author":"Rivas","year":"2010","journal-title":"Viruses"},{"key":"10.1038\/mto.2015.17_bib29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01850","article-title":"Integration of interferon-alpha\/beta signalling to p53 responses in tumour suppression and antiviral defence","volume":"424","author":"Takaoka","year":"2003","journal-title":"Nature"},{"key":"10.1038\/mto.2015.17_bib30","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1134\/S0006297910130110","article-title":"Constitutive and induced functions of the p53 gene","volume":"75","author":"Zheltukhin","year":"2010","journal-title":"Biochemistry (Mosc)"},{"key":"10.1038\/mto.2015.17_bib31","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1134\/S0006297907130019","article-title":"Versatile functions of p53 protein in multicellular organisms","volume":"72","author":"Chumakov","year":"2007","journal-title":"Biochemistry (Mosc)"},{"key":"10.1038\/mto.2015.17_bib32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mto.2015.17_bib33","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/382816a0","article-title":"Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage","volume":"382","author":"Tanaka","year":"1996","journal-title":"Nature"},{"key":"10.1038\/mto.2015.17_bib34","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1091\/mbc.e05-09-0858","article-title":"DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation","volume":"17","author":"Moiseeva","year":"2006","journal-title":"Mol Biol Cell"},{"key":"10.1038\/mto.2015.17_bib35","doi-asserted-by":"crossref","first-page":"E89","DOI":"10.1073\/pnas.1216922110","article-title":"p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs","volume":"110","author":"Leonova","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mto.2015.17_bib36","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/mto.2015.17_bib37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cyto.2009.06.006","article-title":"Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta","volume":"47","author":"Bartee","year":"2009","journal-title":"Cytokine"},{"key":"10.1038\/mto.2015.17_bib38","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/ph3020406","article-title":"Deregulation of interferon signaling in malignant cells","volume":"3","author":"Katsoulidis","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1038\/mto.2015.17_bib39","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1038\/mto.2015.17_bib40","first-page":"9","article-title":"Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus based oncolysis","volume":"9","author":"Berchtold","year":"2013","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.17_bib41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1038\/mto.2015.17_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/imt.10.6","article-title":"New perspectives in cancer virotherapy: bringing the immune system into play","volume":"2","author":"Boisgerault","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1038\/mto.2015.17_bib43","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/hum.2009.135","article-title":"The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon","volume":"20","author":"Prestwich","year":"2009","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mto.2015.17_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/gt.2011.205","article-title":"Measles virus causes immunogenic cell death in human melanoma","volume":"20","author":"Donnelly","year":"2013","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2015.17_bib45","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.jvir.2013.05.040","article-title":"Oncolytic virotherapy","volume":"24","author":"Sze","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"10.1038\/mto.2015.17_bib46","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1158\/1078-0432.CCR-13-0246","article-title":"Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells","volume":"19","author":"Tai","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.17_bib47","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nbt937","article-title":"Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins","volume":"22","author":"Yu","year":"2004","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mto.2015.17_bib48","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1038\/mt.2012.128","article-title":"Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine","volume":"20","author":"Lemay","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.17_bib49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-1-4614-7651-1_6","article-title":"Paramyxovirus entry","volume":"790","author":"Bossart","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"10.1038\/mto.2015.17_bib50","first-page":"73","article-title":"Sialic acid receptors of viruses","volume":"7","author":"Matrosovich","year":"2013","journal-title":"Top Curr Chem"},{"key":"10.1038\/mto.2015.17_bib51","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1158\/0008-5472.CAN-14-0728","article-title":"Sialic acids sweeten a tumor's life","volume":"74","author":"B\u00fcll","year":"2014","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib52","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/ijc.24234","article-title":"Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle","volume":"124","author":"Kawaguchi","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1038\/mto.2015.17_bib53","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.cgt.7700823","article-title":"Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer","volume":"12","author":"Myers","year":"2005","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mto.2015.17_bib54","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1158\/0008-5472.CAN-04-0884","article-title":"High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus","volume":"64","author":"Anderson","year":"2004","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2407-7-73","article-title":"Nectin-4 is a new histological and serological tumor associated marker for breast cancer","volume":"7","author":"Fabre-Lafay","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1038\/mto.2015.17_bib56","doi-asserted-by":"crossref","first-page":"15011","DOI":"10.1038\/mto.2015.11","article-title":"Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency","volume":"2","author":"Matveeva","year":"2015","journal-title":"Molecular Therapy \u2014 Oncolytics"},{"key":"10.1038\/mto.2015.17_bib57","series-title":"The Paramyxoviruses","author":"Kingsbury","year":"1991"},{"key":"10.1038\/mto.2015.17_bib58","series-title":"Paramyxoviruses","author":"Enders","year":"1996"},{"key":"10.1038\/mto.2015.17_bib59","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.4049\/jimmunol.1001635","article-title":"Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting","volume":"185","author":"Cohen","year":"2010","journal-title":"J Immunol"},{"key":"10.1038\/mto.2015.17_bib60","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4049\/jimmunol.139.1.262","article-title":"Cell surface sialic acid influences tumor cell recognition in the mixed lymphocyte reaction","volume":"139","author":"Powell","year":"1987","journal-title":"J Immunol"},{"key":"10.1038\/mto.2015.17_bib61","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/clpt.2010.211","article-title":"Therapeutic potential of oncolytic measles virus: promises and challenges","volume":"88","author":"Galanis","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1038\/mto.2015.17_bib62","first-page":"1492","article-title":"Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth","volume":"60","author":"Bateman","year":"2000","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib63","first-page":"6566","article-title":"Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells","volume":"62","author":"Bateman","year":"2002","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib64","doi-asserted-by":"crossref","first-page":"8527","DOI":"10.1128\/JVI.00807-12","article-title":"Membrane fusion-mediated autophagy induction enhances morbillivirus cell-to-cell spread","volume":"86","author":"Delpeut","year":"2012","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.17_bib65","doi-asserted-by":"crossref","first-page":"e1003599","DOI":"10.1371\/journal.ppat.1003599","article-title":"Sustained autophagy contributes to measles virus infectivity","volume":"9","author":"Richetta","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1038\/mto.2015.17_bib66","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00705-012-1248-4","article-title":"Whole genome sequencing and biological characterization of Duck\/JS\/10, a new lentogenic class I Newcastle disease virus","volume":"157","author":"Meng","year":"2012","journal-title":"Arch Virol"},{"key":"10.1038\/mto.2015.17_bib67","doi-asserted-by":"crossref","first-page":"43651","DOI":"10.1074\/jbc.M112.399964","article-title":"RNase L induces autophagy via c-Jun N-terminal kinase and double-stranded RNA-dependent protein kinase signaling pathways","volume":"287","author":"Siddiqui","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1038\/mto.2015.17_bib68","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-06-1615","article-title":"Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells","volume":"67","author":"Kurooka","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib69","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00262-007-0351-y","article-title":"Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation","volume":"57","author":"Fujihara","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1038\/mto.2015.17_bib70","series-title":"Fields Virology, 5th edn","first-page":"1449","author":"Lamb","year":"2007"},{"issue":"Pt 2","key":"10.1038\/mto.2015.17_bib71","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1099\/vir.0.82150-0","article-title":"Newcastle disease virus may enter cells by caveolae-mediated endocytosis","volume":"88","author":"Cant\u00edn","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1038\/mto.2015.17_bib72","first-page":"6396","article-title":"Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy","volume":"60","author":"Higuchi","year":"2000","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib73","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1094\/MPMI-09-10-0214","article-title":"The evolutionary genetics of emerging plant RNA viruses","volume":"24","author":"Elena","year":"2011","journal-title":"Mol Plant Microbe Interact"},{"issue":"Pt 10","key":"10.1038\/mto.2015.17_bib74","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1099\/vir.0.19277-0","article-title":"Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses","volume":"84","author":"Chare","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1038\/mto.2015.17_bib75","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/v3081358","article-title":"Homologous recombination in negative sense RNA viruses","volume":"3","author":"Han","year":"2011","journal-title":"Viruses"},{"issue":"Pt 7","key":"10.1038\/mto.2015.17_bib76","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1099\/vir.0.80986-0","article-title":"Paramyxovirus mRNA editing, the \u201crule of six\u201d and error catastrophe: a hypothesis","volume":"86","author":"Kolakofsky","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1038\/mto.2015.17_bib77","series-title":"Infectious Diseases of Mice and Rats","year":"1991"},{"key":"10.1038\/mto.2015.17_bib78","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.2741\/2847","article-title":"New cancer therapy using genetically-engineered oncolytic Sendai virus vector","volume":"13","author":"Kinoh","year":"2008","journal-title":"Front Biosci"},{"key":"10.1038\/mto.2015.17_bib79","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1158\/1078-0432.CCR-04-1485","article-title":"Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats","volume":"11","author":"Iwadate","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.17_bib80","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/gt.2008.161","article-title":"Complete elimination of established neuroblastoma by synergistic action of gamma-irradiation and DCs treated with rSeV expressing interferon-beta gene","volume":"16","author":"Tatsuta","year":"2009","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2015.17_bib81","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.2741\/2809","article-title":"Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen","volume":"13","author":"Yonemitsu","year":"2008","journal-title":"Front Biosci"},{"key":"10.1038\/mto.2015.17_bib82","series-title":"Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic Sendai virus","author":"Senin","year":"2014"},{"key":"10.1038\/mto.2015.17_bib83","author":"Senin","year":"2014","journal-title":"Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic Sendai virus"},{"key":"10.1038\/mto.2015.17_bib84","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/1078-0432.CCR-12-1947","article-title":"Systemic administration of a novel immune-stimulatory pseudovirion suppresses lung metastatic melanoma by regionally enhancing IFN-\u03b3 production","volume":"19","author":"Saga","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.17_bib85","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM196409242711302","article-title":"Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report","volume":"271","author":"Wheelock","year":"1964","journal-title":"N Engl J Med"},{"key":"10.1038\/mto.2015.17_bib86","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3181\/00379727-90-21945","article-title":"Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo","volume":"90","author":"Flanagan","year":"1955","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1038\/mto.2015.17_bib87","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1586\/erv.10.124","article-title":"Use of attenuated paramyxoviruses for cancer therapy","volume":"9","author":"Lech","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1038\/mto.2015.17_bib88","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-61779-340-0_13","article-title":"Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation","volume":"797","author":"Fournier","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1038\/mto.2015.17_bib89","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/fmb.12.4","article-title":"Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions","volume":"7","author":"Zamarin","year":"2012","journal-title":"Future Microbiol"},{"key":"10.1038\/mto.2015.17_bib90","first-page":"26","article-title":"Safety and clinical usage of Newcastle disease virus in cancer therapy","volume":"718710","author":"Lam","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1038\/mto.2015.17_bib91","series-title":"Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer","author":"Csatary","year":"2011"},{"key":"10.1038\/mto.2015.17_bib92","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0022-4804(92)90310-V","article-title":"Newcastle disease virus selectively kills human tumor cells","volume":"52","author":"Reichard","year":"1992","journal-title":"J Surg Res"},{"key":"10.1038\/mto.2015.17_bib93","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ijc.21821","article-title":"Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence","volume":"119","author":"Fiola","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1038\/mto.2015.17_bib94","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1128\/JVI.02490-06","article-title":"p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines","volume":"81","author":"F\u00e1bi\u00e1n","year":"2007","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.17_bib95","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.gt.3300787","article-title":"Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus","volume":"6","author":"Schirrmacher","year":"1999","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2015.17_bib96","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/mt.2008.286","article-title":"Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses","volume":"17","author":"Zamarin","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.17_bib97","first-page":"125","article-title":"Induction of apoptosis by a Newcastle disease virus vaccine (MTH-68\/H) in PC12 rat phaeochromocytoma cells","volume":"21","author":"F\u00e1bi\u00e1n","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1038\/mto.2015.17_bib98","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00045391-200307000-00008","article-title":"Newcastle disease virus-induced apoptosis in PC12 pheochromocytoma cells","volume":"10","author":"Szeber\u00e9nyi","year":"2003","journal-title":"Am J Ther"},{"key":"10.1038\/mto.2015.17_bib99","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF01198099","article-title":"The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells","volume":"121","author":"Tzadok-David","year":"1995","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1038\/mto.2015.17_bib100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF01212880","article-title":"Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells","volume":"122","author":"Bar-Eli","year":"1996","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1038\/mto.2015.17_bib101","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/jnci\/86.16.1228","article-title":"Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy","volume":"86","author":"Lorence","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/mto.2015.17_bib102","first-page":"6017","article-title":"Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy","volume":"54","author":"Lorence","year":"1994","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0304-3835(01)00617-6","article-title":"Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration","volume":"172","author":"Phuangsab","year":"2001","journal-title":"Cancer Lett"},{"key":"10.1038\/mto.2015.17_bib104","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1158\/0008-5472.CAN-07-1025","article-title":"Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus","volume":"67","author":"Vigil","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/mt.2009.231","article-title":"Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma","volume":"18","author":"Altomonte","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.17_bib106","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00109-010-0605-6","article-title":"Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer","volume":"88","author":"Song","year":"2010","journal-title":"J Mol Med (Berl)"},{"key":"10.1038\/mto.2015.17_bib107","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1517\/14712598.4.10.1685","article-title":"Oncolytic measles viruses for cancer therapy","volume":"4","author":"Nakamura","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1038\/mto.2015.17_bib108","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2174\/156652308784746459","article-title":"Measles virus as an oncolytic vector platform","volume":"8","author":"Blechacz","year":"2008","journal-title":"Curr Gene Ther"},{"key":"10.1038\/mto.2015.17_bib109","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/gt.2012.62","article-title":"Oncolytic measles virus strains have significant antitumor activity against glioma stem cells","volume":"20","author":"Allen","year":"2013","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2015.17_bib110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM196007282630401","article-title":"Studies on an attenuated measles-virus vaccine. I. Development and preparations of the vaccine: technics for assay of effects of vaccination","volume":"263","author":"Enders","year":"1960","journal-title":"N Engl J Med"},{"key":"10.1038\/mto.2015.17_bib111","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood.V97.12.3746","article-title":"Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice","volume":"97","author":"Grote","year":"2001","journal-title":"Blood"},{"key":"10.1038\/mto.2015.17_bib112","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1182\/blood-2003-07-2233","article-title":"Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter","volume":"103","author":"Dingli","year":"2004","journal-title":"Blood"},{"key":"10.1038\/mto.2015.17_bib113","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/neuonc\/noq057","article-title":"Treatment of medulloblastoma with a modified measles virus","volume":"12","author":"Studebaker","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1038\/mto.2015.17_bib114","first-page":"2462","article-title":"Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme","volume":"63","author":"Phuong","year":"2003","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib115","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/hep.21437","article-title":"Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma","volume":"44","author":"Blechacz","year":"2006","journal-title":"Hepatology"},{"key":"10.1038\/mto.2015.17_bib116","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/mt.2009.218","article-title":"Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter","volume":"17","author":"Msaouel","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.17_bib117","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10549-006-9200-5","article-title":"A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer","volume":"99","author":"McDonald","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/mto.2015.17_bib118","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10549-009-0602-z","article-title":"Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model","volume":"122","author":"Iankov","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/mto.2015.17_bib119","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.cgt.7700948","article-title":"Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model","volume":"13","author":"Peng","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mto.2015.17_bib120","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/mt.2013.16","article-title":"DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety","volume":"21","author":"Friedrich","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.17_bib121","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-61779-340-0_11","article-title":"Oncolytic measles virus retargeting by ligand display","volume":"797","author":"Msaouel","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1038\/mto.2015.17_bib122","first-page":"43","article-title":"Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview","volume":"11","author":"Msaouel","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1038\/mto.2015.17_bib123","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.2174\/138920112800958896","article-title":"Attenuated oncolytic measles virus strains as cancer therapeutics","volume":"13","author":"Msaouel","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1038\/mto.2015.17_bib124","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2013.05.004","article-title":"Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase","volume":"130","author":"Hartkopf","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1038\/mto.2015.17_bib125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/humc.2013.127","article-title":"Pulsed versus continuous application of the prodrug 5-fluorocytosine to enhance the oncolytic effectiveness of a measles vaccine virus armed with a suicide gene","volume":"25","author":"Yurttas","year":"2014","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1038\/mto.2015.17_bib126","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3892\/ijo.2013.1914","article-title":"Primary resistance phenomena to oncolytic measles vaccine viruses","volume":"43","author":"Noll","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1038\/mto.2015.17_bib127","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1089\/hum.2012.136","article-title":"A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma","volume":"24","author":"Lange","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mto.2015.17_bib128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/humc.2012.242","article-title":"Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaques","volume":"24","author":"V\u00f6lker","year":"2013","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1038\/mto.2015.17_bib129","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/cgt.2013.61","article-title":"Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application","volume":"20","author":"Tanemura","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mto.2015.17_bib130","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1016\/j.vaccine.2004.01.053","article-title":"Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults","volume":"22","author":"Slobod","year":"2004","journal-title":"Vaccine"},{"key":"10.1038\/mto.2015.17_bib131","series-title":"Newcastle Disease Virus (Paramyxoviridae) Encyclopedia of Virology","first-page":"1020","author":"Emmerson","year":"1999"},{"key":"10.1038\/mto.2015.17_bib132","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.2460\/javma.2003.222.1534","article-title":"Avian influenza and Newcastle disease","volume":"222","author":"Swayne","year":"2003","journal-title":"J Am Vet Med Assoc"},{"key":"10.1038\/mto.2015.17_bib133","first-page":"619","article-title":"Attenuated veterinary virus vaccine for the treatment of cancer","volume":"17","author":"Csatary","year":"1993","journal-title":"Cancer Detect Prev"},{"key":"10.1038\/mto.2015.17_bib134","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/B:NEON.0000021735.85511.05","article-title":"MTH-68\/H oncolytic viral treatment in human high-grade gliomas","volume":"67","author":"Csatary","year":"2004","journal-title":"J Neurooncol"},{"key":"10.1038\/mto.2015.17_bib135","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","article-title":"Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme","volume":"13","author":"Freeman","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.17_bib136","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/156800907780058853","article-title":"Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus","volume":"7","author":"Lorence","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1038\/mto.2015.17_bib137","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-06-1817","article-title":"An optimized clinical regimen for the oncolytic virus PV701","volume":"13","author":"Hotte","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.17_bib138","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02987752","article-title":"A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate","volume":"9","author":"Cassel","year":"1992","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"10.1038\/mto.2015.17_bib139","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/BF03401771","article-title":"A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire","volume":"4","author":"Batliwalla","year":"1998","journal-title":"Mol Med"},{"key":"10.1038\/mto.2015.17_bib140","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1158\/0008-5472.CAN-04-1545","article-title":"Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells","volume":"64","author":"Karcher","year":"2004","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib141","first-page":"173","article-title":"Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine","volume":"62","author":"Herold-Mende","year":"2005","journal-title":"Adv Otorhinolaryngol"},{"key":"10.1038\/mto.2015.17_bib142","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-008-0526-1","article-title":"Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial","volume":"58","author":"Schulze","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1038\/mto.2015.17_bib143","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/978-1-59745-561-9_30","article-title":"Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer","volume":"542","author":"Schirrmacher","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1038\/mto.2015.17_bib144","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","article-title":"Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers","volume":"20","author":"Pecora","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1038\/mto.2015.17_bib145","first-page":"945","article-title":"Antitumor effects of Newcastle disease virus in vivo: local versus systemic effects","volume":"18","author":"Schirrmacher","year":"2001","journal-title":"Int J Oncol"},{"key":"10.1038\/mto.2015.17_bib146","first-page":"618","article-title":"Overview of phase I studies of intravenous administration of PV701, an oncolytic virus","volume":"5","author":"Lorence","year":"2003","journal-title":"Curr Opin Mol Ther"},{"key":"10.1038\/mto.2015.17_bib147","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1158\/1078-0432.CCR-05-2038","article-title":"A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization","volume":"12","author":"Laurie","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.17_bib148","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/biology2020587","article-title":"Antitumor virotherapy by attenuated measles virus","volume":"2","author":"Guillerme","year":"2013","journal-title":"Biology"},{"key":"10.1038\/mto.2015.17_bib149","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/blood-2004-11-4558","article-title":"Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells","volume":"106","author":"Heinzerling","year":"2005","journal-title":"Blood"},{"key":"10.1038\/mto.2015.17_bib150","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Galanis","year":"2010","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib151","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Russell","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1038\/mto.2015.17_bib152","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","article-title":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer","volume":"75","author":"Galanis","year":"2015","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib153","first-page":"487","article-title":"Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus","volume":"12","author":"Shimizu","year":"1988","journal-title":"Cancer Detect Prev"},{"key":"10.1038\/mto.2015.17_bib154","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/1097-0142(197412)34:6<1907::AID-CNCR2820340609>3.0.CO;2-4","article-title":"Treatment of human cancer with mumps virus","volume":"34","author":"Asada","year":"1974","journal-title":"Cancer"},{"key":"10.1038\/mto.2015.17_bib155","first-page":"37","article-title":"Studies on the use of mumps virus for treatment of human cancer","volume":"21","author":"Okuno","year":"1978","journal-title":"Biken J"},{"key":"10.1038\/mto.2015.17_bib156","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1089\/hum.2012.205","article-title":"Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine","volume":"24","author":"Grossardt","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mto.2015.17_bib157","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events","volume":"12","author":"Weber","year":"2007","journal-title":"Oncologist"},{"key":"10.1038\/mto.2015.17_bib158","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1177\/1060028015586218","article-title":"Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology","volume":"49","author":"Barbee","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1038\/mto.2015.17_bib159","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1038\/mto.2015.17_bib160","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2014.160","article-title":"CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy","volume":"22","author":"Engeland","year":"2014","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.17_bib161","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/cgt.2014.40","article-title":"MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus","volume":"21","author":"Baertsch","year":"2014","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mto.2015.17_bib162","doi-asserted-by":"crossref","first-page":"7694","DOI":"10.1158\/0008-5472.CAN-06-0538","article-title":"Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases","volume":"66","author":"Springfeld","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.17_bib163","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1593\/neo.08166","article-title":"A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness","volume":"10","author":"Coppola","year":"2008","journal-title":"Neoplasia"},{"key":"10.1038\/mto.2015.17_bib164","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/1098-2744(200006)28:2<63::AID-MC1>3.0.CO;2-C","article-title":"The proprotein convertases furin and PACE4 play a significant role in tumor progression","volume":"28","author":"Bassi","year":"2000","journal-title":"Mol Carcinog"},{"key":"10.1038\/mto.2015.17_bib165","doi-asserted-by":"crossref","first-page":"10326","DOI":"10.1073\/pnas.191199198","article-title":"Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells","volume":"98","author":"Bassi","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mto.2015.17_bib166","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mc.1057","article-title":"Elevated furin expression in aggressive human head and neck tumors and tumor cell lines","volume":"31","author":"Bassi","year":"2001","journal-title":"Mol Carcinog"},{"key":"10.1038\/mto.2015.17_bib167","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0002-9440(10)63838-2","article-title":"Increased furin activity enhances the malignant phenotype of human head and neck cancer cells","volume":"162","author":"Bassi","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1038\/mto.2015.17_bib168","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1593\/neo.12166","article-title":"Transgenic overexpression of the proprotein convertase furin enhances skin tumor growth","volume":"14","author":"Fu","year":"2012","journal-title":"Neoplasia"},{"key":"10.1038\/mto.2015.17_bib169","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/gt.2009.14","article-title":"Genetically engineered Newcastle disease virus for malignant melanoma therapy","volume":"16","author":"Zamarin","year":"2009","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2015.17_bib170","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1158\/1535-7163.MCT-10-0090","article-title":"Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma","volume":"9","author":"Silberhumer","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/mto.2015.17_bib171","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/hed.21609","article-title":"Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer","volume":"33","author":"Li","year":"2011","journal-title":"Head Neck"},{"key":"10.1038\/mto.2015.17_bib172","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/JVI.73.6.5001-5009.1999","article-title":"Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence","volume":"73","author":"Peeters","year":"1999","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.17_bib173","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1128\/JVI.00241-06","article-title":"Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death","volume":"80","author":"Elankumaran","year":"2006","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.17_bib174","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1751-7915.2011.00296.x","article-title":"Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses","volume":"5","author":"Altomonte","year":"2012","journal-title":"Microb Biotechnol"},{"key":"10.1038\/mto.2015.17_bib175","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/sj.gt.3302272","article-title":"Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases","volume":"11","author":"Kinoh","year":"2004","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2015.17_bib176","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/gt.2008.167","article-title":"Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies","volume":"16","author":"Kinoh","year":"2009","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2015.17_bib177","doi-asserted-by":"crossref","first-page":"e90508","DOI":"10.1371\/journal.pone.0090508","article-title":"Attenuated and protease-profile modified sendai virus vectors as a new tool for virotherapy of solid tumors","volume":"9","author":"Zimmermann","year":"2014","journal-title":"PLoS One"},{"key":"10.1038\/mto.2015.17_bib178","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","article-title":"CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice","volume":"22","author":"Thompson","year":"1994","journal-title":"Nucleic Acids Res"},{"key":"10.1038\/mto.2015.17_bib179","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/molbev\/msr121","article-title":"MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods","volume":"28","author":"Tamura","year":"2011","journal-title":"Mol Biol Evol"},{"key":"10.1038\/mto.2015.17_bib180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1099\/0022-1317-80-1-131","article-title":"Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae","volume":"80","author":"de Leeuw","year":"1999","journal-title":"J Gen Virol"},{"key":"10.1038\/mto.2015.17_bib181","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1200\/JCO.2004.09.038","article-title":"Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit","volume":"22","author":"Steiner","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770516300195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770516300195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:17:48Z","timestamp":1762496268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770516300195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":181,"alternative-id":["S2372770516300195"],"URL":"https:\/\/doi.org\/10.1038\/mto.2015.17","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolysis by paramyxoviruses: preclinical and clinical studies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mto.2015.17","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Official journal of the American Society of Gene & Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"15017"}}